GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Burzynski Research Institute Inc (OTCPK:BZYR) » Definitions » Debt-to-Asset

BZYR (Burzynski Research Institute) Debt-to-Asset : 0.00 (As of Nov. 2024)


View and export this data going back to . Start your Free Trial

What is Burzynski Research Institute Debt-to-Asset?

Burzynski Research Institute's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2024 was $0.00 Mil. Burzynski Research Institute's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2024 was $0.00 Mil. Burzynski Research Institute's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Nov. 2024 was $0.00 Mil. Burzynski Research Institute's debt to asset for the quarter that ended in Nov. 2024 was 0.00.


Burzynski Research Institute Debt-to-Asset Historical Data

The historical data trend for Burzynski Research Institute's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burzynski Research Institute Debt-to-Asset Chart

Burzynski Research Institute Annual Data
Trend Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Burzynski Research Institute Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Burzynski Research Institute's Debt-to-Asset

For the Biotechnology subindustry, Burzynski Research Institute's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Burzynski Research Institute's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Burzynski Research Institute's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Burzynski Research Institute's Debt-to-Asset falls into.


;
;

Burzynski Research Institute Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Burzynski Research Institute's Debt-to-Asset for the fiscal year that ended in Feb. 2024 is calculated as

Burzynski Research Institute's Debt-to-Asset for the quarter that ended in Nov. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Burzynski Research Institute  (OTCPK:BZYR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Burzynski Research Institute Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Burzynski Research Institute's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Burzynski Research Institute Business Description

Traded in Other Exchanges
N/A
Address
9432 Katy Freeway, Houston, TX, USA, 77055
Burzynski Research Institute Inc operates primarily as a research and development facility of Antineoplaston drugs currently being tested for the use in the treatment of cancer, and provides consulting services.
Executives
Monika Szopa-paszkowiak director 9432 KATY FWY #200, HOUSTON TX 77055
Frederick Richard Schiff director 9432 KATY FREEWAY, HOUSTON TX 77055
Barbara Burzynski director, 10 percent owner 9432 KATY FREEWAY, HOUSTON TX 77055
Carlton Hazlewood director 9432 KATY FREEWAY, HOUSTON TX 77055
Patryk Goscianski officer: Secretary and Treasurer 9432 KATY FREEWAY, HOUSTON TX 77055
Gregory Burzynski director 9432 KATY FREEWAY, HOUSTON TX 77055
Tomasz Janicki officer: VP of Clinical Trials 9432 KATY FREEWAY, HOUSTON TX 77055
Michael Driscoll director 9432 KATY FREEWAY, HOUSTON TX 77055
Stanislaw Burzynski director, 10 percent owner, officer: President 9432 KATY FREEWAY, HOUSTON TX 77055
Dudley Reece Anderson officer: Chief Financial Officer 9432 OLD KATY RD., SUITE 200, HOUSTON TX 77055

Burzynski Research Institute Headlines

No Headlines